Insulin‐like growth factor‐I analogue protects muscles of dystrophic mdx mice from contraction‐mediated damage
- 14 October 2008
- journal article
- Published by Wiley in Experimental Physiology
- Vol. 93 (11) , 1190-1198
- https://doi.org/10.1113/expphysiol.2008.042838
Abstract
Contraction-mediated injury is a major contributing factor to the pathophysiology of muscular dystrophy and therefore therapies that can attenuate this type of injury have clinical relevance. Systemic administration of insulin-like growth factor-I (IGF-I) has been shown to improve muscle function in dystrophic mdx mice, an effect associated with a shift towards a more oxidative muscle phenotype and a reduced susceptibility to contraction-mediated damage. The actions of IGF-I in vivo are modulated by IGF binding proteins (IGFBPs), which generally act to inhibit IGF-I signalling. We tested the hypothesis that an analogue of IGF-I (LR IGF-I), which has significantly reduced binding affinity for IGFBPs, would improve the dystrophic pathology by reducing the susceptibility to muscle injury. Dystrophic mdx and wild-type (C57BL/10) mice were administered LR IGF-I continuously (∼1.5 mg kg−1 day−1) via osmotic mini-pump for 4 weeks. Administration of LR IGF-I reduced the susceptibility of extensor digitorum longus, soleus and diaphragm muscles to contraction damage, as evident from lower force deficits after a protocol of lengthening contractions. In contrast to the mechanism of protection conferred by administration of IGF-I, the protection conferred by LR IGF-I was independent of changes in muscle fatigue and oxidative metabolism. This study further indicates that modulation of IGF-I signalling has therapeutic potential for muscular diseases.Keywords
This publication has 31 references indexed in Scilit:
- Modulation of Insulin-like Growth Factor (IGF)-I and IGF-Binding Protein Interactions Enhances Skeletal Muscle Regeneration and Ameliorates the Dystrophic Pathology in mdx MiceThe American Journal of Pathology, 2007
- Systemic administration of IGF-I enhances oxidative status and reduces contraction-induced injury in skeletal muscles of mdx dystrophic miceAmerican Journal of Physiology-Endocrinology and Metabolism, 2006
- Comparative evaluation of IGF-I gene transfer and IGF-I protein administration for enhancing skeletal muscle regeneration after injuryGene Therapy, 2006
- Interleukin-15 Administration Improves Diaphragm Muscle Pathology and Function in Dystrophic mdx MiceThe American Journal of Pathology, 2005
- β2-Agonist administration increases sarcoplasmic reticulum Ca2+-ATPase activity in aged rat skeletal muscleAmerican Journal of Physiology-Endocrinology and Metabolism, 2005
- ROLE OF CONTRACTION‐INDUCED INJURY IN THE MECHANISMS OF MUSCLE DAMAGE IN MUSCULAR DYSTROPHYClinical and Experimental Pharmacology and Physiology, 2004
- Administration of insulin‐like growth factor‐I improves fatigue resistance of skeletal muscles from dystrophic mdx miceMuscle & Nerve, 2004
- The muscular dystrophiesPublished by Elsevier ,2002
- Higher content of insulin-like growth factor-I in dystrophic mdx mouse: potential role in the spontaneous regeneration through an electrophysiological investigation of muscle functionNeuromuscular Disorders, 1999
- Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injectionJournal of Endocrinology, 1996